(Total Views: 667)
Posted On: 06/13/2019 5:50:12 PM
Post# of 416
NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Announces Rollout Strategy of SofPulse Post-Operative Opioid Alternative to Hospitals Across U.S.
Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, this morning announced its strategy for the national rollout of its SofPulse targeted pulsed electromagnetic field (“tPEMF”) therapy device to hospitals throughout the United States. Per the update, Endonovo has recently entered agreements with six master distributors and has hired approximately 40 sales associates, and, within the next 18 months, intends to have 300 sales representatives and be in the evaluation stage with 600 hospitals. “After careful consideration and discussions, and in accordance with our internal budgets, we have reached the point at which we can confidently announce our national rollout plan and strategy,” Endonovo CEO Alan Collier stated in the news release. “We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse device supports our plans to be in hospitals throughout all 50 states by 2020. With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, this morning announced its strategy for the national rollout of its SofPulse targeted pulsed electromagnetic field (“tPEMF”) therapy device to hospitals throughout the United States. Per the update, Endonovo has recently entered agreements with six master distributors and has hired approximately 40 sales associates, and, within the next 18 months, intends to have 300 sales representatives and be in the evaluation stage with 600 hospitals. “After careful consideration and discussions, and in accordance with our internal budgets, we have reached the point at which we can confidently announce our national rollout plan and strategy,” Endonovo CEO Alan Collier stated in the news release. “We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse device supports our plans to be in hospitals throughout all 50 states by 2020. With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
